Assignee
ADRENOMED AG
DE·8 granted patents·9 pending applications·5 citations·filing 2012–2023
Top patents by PatentIndex Score
17 records- 0195US12338281B2Anti-adrenomedullin antibodies and pharmaceutical compositions thereofADRENOMED AG·Filed 2023·Granted Jun 24, 2025·1 cites·6 claims
- 0282US9304127B2Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment for use in therapyADRENOMED AG·Filed 2012·Granted Apr 5, 2016·2 cites·18 claims
- 0377US9140696B2Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-IG scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute conditionADRENOMED AG·Filed 2012·Granted Sep 22, 2015·1 cites·26 claims
- 0475US10221238B2Method of modulating the activity of adrenomedullin in a subject in need of therapeutic intervention for organ dysfunction or organ failure associated with adranomedullin (ADM) activity by administering an anti-adrenomedullin (ADM) antibody or an anti-ADM antibody fragment to the subjectADRENOMED AG·Filed 2016·Granted Mar 5, 2019·1 cites·21 claims
- 0572US10800842B2Anti-adrenomedullin (ADM) monoclonal antibodies and anti-ADM monoclonal antibody fragments that bind to adrenomedullinADRENOMED AG·Filed 2018·Granted Oct 13, 2020·0 cites·11 claims
- 0668US11673949B2Method of modulating the adrenomedullin (ADM) activity of a patient by administering to the patient an anti-ADM antibody or fragment thereof that specifically binds to mature human ADMADRENOMED AG·Filed 2018·Granted Jun 13, 2023·0 cites·13 claims
- 0763US2025304671A1Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragmentADRENOMED AG·Filed 2023·Application pending·0 cites
- 0862US2022041703A1Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereofADRENOMED AG·Filed 2021·Application pending·0 cites
- 0960US2014328853A1Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute conditionADRENOMED AG·Filed 2012·Application pending·0 cites
- 1056US2014314775A1Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment of anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute diseaseADRENOMED AG·Filed 2012·Application pending·0 cites
- 1156US2023250166A1Anti-adrenomedullin (adm) binder for use in therapy of patients in shockADRENOMED AG·Filed 2021·Application pending·0 cites
- 1256US2023104578A1Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shockADRENOMED AG·Filed 2021·Application pending·0 cites
- 1352US10227405B2Methods of modulating the activity of adrenomedullin in a subject in need of regulation of fluid balance by administering an anti-adrenomedullin (ADM) antibody or an anti-ADM antibody fragmentADRENOMED AG·Filed 2016·Granted Mar 12, 2019·0 cites·16 claims
- 1451US2020299372A1Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereofADRENOMED AG·Filed 2017·Application pending·0 cites
- 1550US2022227854A1Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illnessADRENOMED AG·Filed 2018·Application pending·0 cites
- 1647US2022268761A1Therapy monitoring under treatment with an anti-adrenomedullin (adm) binderADRENOMED AG·Filed 2018·Application pending·0 cites
- 1745US9402900B2Methods of modulating adrenomedullin by administering an anti-adrenomedullin (ADM) antibodyADRENOMED AG·Filed 2012·Granted Aug 2, 2016·0 cites·22 claims
Join the waitlist — get patent alerts
Get an alert when ADRENOMED AG files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →